Navigation Links
Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
Date:8/22/2014

La Jolla, CA Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc. combats three types of human papillomavirus, including the two that cause 70 percent of all cervical cancer.

When tested in several cultured human cell models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according to Louise T. Chow, Ph.D. and Thomas Broker, Ph.D., who presented the findings at the Seattle conference. The National Institute of Allergy and Infectious Diseases in the National Institutes of Health funded Chow's work at the University of Alabama, Birmingham.

"HTI-1968 is potent and selective, inhibiting the growth of these high-risk HPV types. Dr. Chow's findings, though early stage, offer hope to millions of women infected by one of these high-risk HPV types, including two that are responsible for 70 percent of cervical cancer cases," said Hera Therapeutics CEO Karl Hostetler, M.D.. Currently surgery is the only therapy available to women who have persistent infection with these types of HPV and show signs of abnormal cells.

Hera Therapeutics is developing a topical, non-surgical approach to treat HPV, which could alter the standard of care while preserving structural integrity of the cervix.

Approximately 96 million people worldwide, men and women, are infected with HPV-16 or HPV-18, according to the Centers for Disease Control. Almost 4,000 women in the U.S. die from invasive cervical cancer each year, according to the CDC.

While cervical cancer vaccines prevent infection from the disease, they are not approved by the FDA for marketing to people over 26-years-old and have not demonstrated efficacy in people already infected with the HPV virus.


'/>"/>
Contact: Terri Somers, Somers Media
terri@somersmedia.com
619-991-2369
Somers Media
Source:Eurekalert

Page: 1

Related biology news :

1. Researchers develop models to study polyelectrolytes, including DNA and RNA
2. Lyme disease risk is year-round in Northwest California, according to new study
3. Recovery reversal seen in Oregon study of returning concussed athletes
4. Study of African dust transport to South America reveals air quality impacts
5. Fish study links brain size to parental duties
6. Climate change will threaten fish by drying out Southwest US streams, study predicts
7. Oregon team to study impacts of climate change on pesky forest insect
8. Study: Worlds primary forests on the brink
9. IU study examines how genes, gender and environment influence substance abuse
10. Scientists study talking turtles in Brazilian Amazon
11. NSAIDs benefit overweight breast cancer patients, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... crystal ball. A new approach to predict whether a ... dose is best could get antibiotics to market faster ... In recent years, scientists worldwide have sounded the alarm: ... Bacteria are increasingly adept at outwitting the traditional antibiotic ...
... variation that may increase susceptibility to osteoporosis, a new study ... Louis demonstrated that in women the variant gene speeds up ... in the bones of the hip. , The study will ... Bone and Mineral Research and is available online. , ...
... been found by Health Canada and the U.S. Food ... or bottled foods. A new study by McGill researchers ... explains the presence of this chemical in a wide ... the October, 2004 issue of Journal of Agricultural and ...
Cached Biology News:New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 2New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 3New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 4Increased risk of osteoporosis associated with gene that one in five people have 2
(Date:5/27/2015)... , May 27, 2015 RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... that it has commenced a public offering of ... shares of its common stock and overallotment purchase ... The shares of common stock, warrants and overallotment ...
(Date:5/27/2015)... DUBLIN , May 26, 2015 ... addition of the "Global Breast Cancer Monoclonal ... offering. Globally, Roche seems to dominate ... largest inventory. Its block buster molecule, Herceptin has ... years. It was found that breast cancer cells ...
(Date:5/27/2015)... Expanding in a big way into ... Biomed Inc. recently inked a deal with Arthur ... Ltd. , the largest endodontic distributor in Japan. The ... for Avalon Biomed, which manufactures Grey MTA Plus® and ... cements that have won renown from dentists around the ...
(Date:5/27/2015)... 27, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today ... 2015. Aviv Boim , CEO ... work to generate functional specific antibodies, targeting identified cancer ... are encouraged by the development progress. We are excited ... which modulate immune checkpoints gain clinical acceptance for cancer ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3
... BOZEN, Italy, December 29 Health Robotics ... agreement with the Devon International Group,(DIG), whereby ... Health Robotics,CytoCare(TM) and i.v.STATION(TM) robots in the ... unique benefits with great appeal to,Government and ...
... 29 AlloSource, one of the nation,s largest non-profit ... use in surgical procedures, will this year sponsor one ... Life float in the January 1 Tournament of Roses ... a tribute to the millions of people touched by ...
... Prescription Product Increases Length, Thickness and Darkness of EyelashesIRVINE, ... AGN ) today announced the U.S. Food and Drug ... as a novel treatment for hypotrichosis of the eyelashes. ... or not enough eyelashes. LATISSE(TM) is the first ...
Cached Biology Technology:Health Robotics Announces Partnership in the People's Republic of China With The Devon International Group 2Health Robotics Announces Partnership in the People's Republic of China With The Devon International Group 3Health Robotics Announces Partnership in the People's Republic of China With The Devon International Group 4AlloSource, Tissue Recipient Join 'Stars of Life' Affected by Organ and Tissue Donation Aboard Donate Life Float in 2009 Rose Parade(R) 2AlloSource, Tissue Recipient Join 'Stars of Life' Affected by Organ and Tissue Donation Aboard Donate Life Float in 2009 Rose Parade(R) 3Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 2Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 3Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 4Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 5Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 6Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 7Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 8Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 9
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
Biology Products: